{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    10,
    13,
    21,
    22,
    54
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 0.7,
  "amendmentDetails": {
    "studyAmendmentImpacts": [
      {
        "id": "impact_1",
        "amendmentId": "amend_3",
        "affectedSection": "Synopsis - No. of patients",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Increased the potential sample size from 2850 up to 4000 patients based on event accrual projections."
      },
      {
        "id": "impact_2",
        "amendmentId": "amend_3",
        "affectedSection": "Section 3.3.2 - Inclusion Criteria",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Refined NT-proBNP thresholds based on LVEF categories and Atrial Fibrillation status."
      }
    ],
    "studyAmendmentReasons": [
      {
        "id": "reason_1",
        "amendmentId": "amend_3",
        "reasonText": "Accumulated blinded data suggested a slower accrual of primary outcome events than originally projected.",
        "category": "Operational",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_2",
        "amendmentId": "amend_3",
        "reasonText": "To ensure the trial is adequately powered to achieve the required number of primary outcome events.",
        "category": "Scientific",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      }
    ],
    "studyChanges": [
      {
        "id": "change_1",
        "amendmentId": "amend_3",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "Synopsis",
        "beforeText": "Approximately 2850 randomised.",
        "afterText": "Approximately 2850 randomised. If the accumulated blinded data suggests a slower accrual of primary outcome events... the number of patients randomised may be increased up to 4000.",
        "summary": "Increased maximum sample size and extended recruitment period."
      },
      {
        "id": "change_2",
        "amendmentId": "amend_3",
        "changeType": "Clarification",
        "instanceType": "StudyChange",
        "sectionNumber": "3.3.2",
        "beforeText": "Elevated NT-proBNP at Visit 1",
        "afterText": "Elevated NT-proBNP at Visit 1... analysed at the Central Laboratory (with specific tiers for EF 36-40, 31-35, and ≤30, adjusted for AF).",
        "summary": "Detailed tiered NT-proBNP inclusion requirements based on Ejection Fraction and AF status."
      },
      {
        "id": "change_3",
        "amendmentId": "amend_3",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "5.3.7",
        "beforeText": "null",
        "afterText": "Ketoacidosis... diagnosis of ketoacidosis in these patients can be based on arterial pH ≤7.30, serum bicarbonate levels <15 and measurement of serum beta-hydroxybutrate levels.",
        "summary": "Added specific diagnostic criteria for ketoacidosis as an Adverse Event of Special Interest (AESI)."
      }
    ],
    "summary": {
      "impactCount": 2,
      "reasonCount": 2,
      "changeCount": 3
    }
  }
}